Amirhossein Abazarikia

Amirhossein Abazarikia

Auto-generated profile, based on publicly available information

Amirhossein Abazarikia

Department of Clinical Pharmacy School of Pharmacy, Shahid Beheshti University of Medical Sciences Tehran Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2022 in Science Advances
Verified
Journal Article
Open access
YLYi Luan
Yi Luan
SYSeok-Yeong Yu
Seok-Yeong Yu
AAAmirhossein Abazarikia
Amirhossein Abazarikia
RDRosemary Dong
Rosemary Dong
SKSo-Youn Kim
So-Youn Kim
Cyclophosphamide and doxorubicin lead to premature ovarian insufficiency as an off-target effect. However, their oocyte death pathway has been debated. Here, we clarified the precise mechanism of ovarian depletion induced by cyclophosphamide and doxorubicin. Dormant oocytes instead of activated oocytes with high PI3K activity were more sensitive to cyclophosphamide. Checkpoint kinase 2 (CHK2) inhibitor rather than GNF2 protected oocytes from cyclophosphamide and doxorubicin, as cyclophosphamide up-regulated p-CHK2 and depleted primordial follicles in Abl1 knockout mice. Contrary to previous reports, TAp63 is pivotal in cyclophosphamide and doxorubicin-induced oocyte death. Oocyte-specific Trp63 knockout mice prevented primordial follicle loss and maintained reproductive function from cyclophosphamide and doxorubicin, indicated by undetectable levels of BAX and cPARP. Here, we demonstrated that TAp63 is fundamental in determining the signaling of oocyte death against DNA damage. This study establishes the role of TAp63 as a target molecule of adjuvant therapies to protect the ovarian reserve from different classes of chemotherapy.

7 July 2020 in Reproduction, Fertility and Development
Verified
Journal Article
Closed access
PDF file
AAAmirhossein Abazarikia
Amirhossein Abazarikia
FAFederica Ariu
Federica Ariu
MRMahsa Rasekhi
Mahsa Rasekhi
MZMahdi Zhandi
Mahdi Zhandi
SLSergio Ledda
Sergio Ledda
This study evaluated the distribution and size of lipid droplets (LDs) in oocytes recovered from young and adult ovine ovaries. Collected oocytes were categorised on the basis of their major diameter (small (SO), 70–90 µm; medium (MO), >90–110 µm; large (LO), >110–130 µm) and were stained with Nile red to detect LDs. In adult and young oocytes, a diffuse pattern distribution of LDs was dominant in all classes except adult LO and young SO and LO. Larger LDs (i.e. >3 µm) were mostly present in young SO and LO, whereas smaller LDs (1–3 µm) were detected in the other adult and young oocyte categories.

19 January 2025 in JGH Open
Verified
Journal Article
Open access
ASAmir Sadeghi
Amir Sadeghi
HSHesamoddin Samar
Hesamoddin Samar
MAMohammad Abbasinazari
Mohammad Abbasinazari
PMParvaneh Mohammadi
Parvaneh Mohammadi
AAAli Abazarikia
Ali Abazarikia
SZShadi Ziaie
Shadi Ziaie
Background and Aim: Oxidative stress has been considered a factor in the development of post‐endoscopic retrograde cholangiopancreatography pancreatitis (PEP). The present clinical trial evaluated whether adding intravenous mesna to rectal indomethacin could prevent or alleviate PEP.Methods: An open‐labeled clinical trial was done on 698 participants undergoing endoscopic retrograde cholangiopancreatography (ERCP). Eligible patients received 100 mg indomethacin suppository 30 min before undergoing ERCP. Randomly, the participants received 400 mg intravenous mesna or nothing 30 min before doing the procedure. The PEP incidence and degree were measured in the patients as the main outcome.Results: The total rate of PEP was equal to 13.7%. No significant difference was seen in the rate and severity of PEP between the mesna plus indomethacin and indomethacin alone arms (14% vs. 13.4%, respectively, p = 0.671). In high‐risk patients, PEP rate and severity were lower in the mesna plus indomethacin group compared with indomethacin alone group and the statistical analysis showed that the difference was significant (41.7% vs. 51.8%, respectively, p = 0.033).Conclusion: In high‐risk patients undergoing ERCP, a combination of intravenous mesna plus rectal indomethacin may decrease the PEP rate and severity.